A growing public health concern is that fewer individuals with documented osteoporosis are receiving effective drug treatment to prevent osteoporotic fractures.1 Evidence of this treatment gap is abundant and comes from multiple countries, health care settings, and demographic populations.Concerns about overtreatment of lower-risk individuals and rare but serious antiresorptive therapy adverse effects have contributed to undertreatment.Fortunately, there is almost universal agreement that individuals with documented hip or vertebral fracture have established osteoporosis, +
No takes yet. Share an insight, caveat, or question.
Douglas C. Bauer (2018) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: